ClinicalTrials.gg
CompletedNCT06403761Updated Feb 27, 2026

Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes

A Phase 1 interventional study of Semaglutide and Cagrilintide in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
158
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing cagrilintide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 4 of them phase 3. cagrilintide · Diabetes Mellitus, Type 2.

Enrollment
11th of 15
158 · median 274
Started
2024
with 5 others
Phase 1
Only one
of the 15
Registered
8th of 15
by date
Lead sponsor
15 of 15
Novo Nordisk A/S

Among the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2, this one is the 11th largest by enrollment, is one of 6 that started in 2024, is the only one in phase 1, and was the 8th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cagrilintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing cagrilintide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study will look at how CagriSema, semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes (T2D). CagriSema is a new investigational medicine that combines two medicines called cagrilintide and semaglutide. Doctors may not yet prescribe CagriSema. Participants will either get CagriSema, semaglutide, cagrilintide, or a ''dummy'' medicine. Which treatment the participants will get is decided by chance. Participants will get the study medicine together with the current daily diabetes medicine metformin. Participants should not take other medicines for diabetes during the study. The study will last for about 42 weeks.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female.
  • Aged 18-75 years (both inclusive) at the time of signing .
  • Diagnosed with type 2 diabetes greater than or equal to (>=) 180 days before screening.
  • Stable daily dose(s) of metformin at effective or maximum tolerated dose, as judged by the investigator for 90 or more days before screening with or without one additional oral antidiabetic drug (OAD), except for the use of glucagon-like peptide-1 (GLP-1) receptor agonists, or sodium-glucose co-transporter-2 (SGLT-2) inhibitors in case of a high risk of cardiovascular disease (as judged by the investigator), or established cardiovascular disease, or chronic kidney disease ( (eGFR) less than (\<) 60 milliliter per minute per 1.73 square meter [ml/min/1.73 m\^2]).
  • (HbA1c) at screening of 6.5-9.5 percent (48-80 millimoles per mole [mmol/mol]) (both inclusive) if on metformin only, or 6.0- 9.0 percent (42-75 mmol/mol) (both inclusive) if on metformin in combination with one other OAD. A minimum of 65% of randomised participants must have HbA1c >= 7.0 % at screening.
  • (BMI) between 25.0 and 45.0 kilogram per square meter (kg/m\^2) (both inclusive) at screening.

Exclusion criteria

Exclusion Criteria:

  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using highly effective method.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • Renal impairment with estimated (eGFR) \< 45 ml/min/1.73 m\^2 at screening.
  • Treatment with any medication for the indication of T2D or weight management other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
158 participants (actual)

Study arms

  • Experimental
    CagriSema

    Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every 4 weeks in a 16-week dose escalation period until target dose of CagriSema is achieved and maintained for 12 weeks.

    Drug: Semaglutide · Drug: Cagrilintide · Drug: Placebo semaglutide · Drug: Placebo cagrilintide

  • Experimental
    Semaglutide

    Participants will receive once-weekly s.c injections of semaglutide at escalating doses every 4 weeks in a 16-week dose escalation period until target dose of CagriSema is achieved and maintained for 12 weeks.

    Drug: Semaglutide · Drug: Placebo semaglutide

  • Experimental
    Cagrilintide

    Participants will receive once-weekly s.c injections of cagrilintide at escalating doses every 4 weeks in a 16-week dose escalation period until target dose of CagriSema is achieved and maintained for 12 weeks.

    Drug: Cagrilintide · Drug: Placebo cagrilintide

  • Placebo comparator
    Placebo

    Participants will receive once-weekly s.c injection of placebo matched to semaglutide and cagrilintide for 28 weeks.

    Drug: Placebo semaglutide · Drug: Placebo cagrilintide

Interventions

  • Participants will receive once-weekly semaglutide subcutaneously.

  • Participants will receive once-weekly cagrilintide subcutaneously.

  • DrugPlacebo semaglutide

    Participants will receive once-weekly placebo matched to semaglutide subcutaneously.

  • DrugPlacebo cagrilintide

    Participants will receive once-weekly placebo matched to cagrilintide subcutaneously.

06

What researchers measure

Primary outcomes

  1. To compare the effect of CagriSema versus placebo: Change in M-value in hyperinsulinaemic euglycaemic clamp (HEC)

    M-value from the HEC is calculated from glucose infusion rate (GIR) over the last 30 minutes of the clamp, corresponding to steady state. M-value is defined as: (GIR150-180 min normalised by body weight \[milligram per minute per kilogram {mg/min/kg}\]). Measured in mg/min/kg.

    Time frame: Baseline to week 28

Secondary outcomes

  1. To compare the effect of CagriSema versus semaglutide, Semaglutide versus placebo and Cagrilintide versus placebo: Change in M-value in HEC

    M-value from the HEC is calculated from GIR over the last 30 minutes of the clamp, corresponding to steady state. M-value is defined as: (GIR150-180 min normalised by body weight \[mg/min/kg\]). Measured in mg/min/kg.

    Time frame: Baseline to week 28

  2. To compare the effect of CagriSema versus placebo, CagriSema versus semaglutide, Semaglutide versus placebo and Cagrilintide versus placebo: Change in M-value in HEC, normalised by lean body mass

    M-value from the HEC is calculated from GIR over the last 30 minutes of the clamp, corresponding to steady state. M-value is defined as: (GIR150-180 min normalised by body weight \[mg/min/kg\]). Measured in mg/min/kg.

    Time frame: Baseline to week 28

  3. Change in first-phase incremental insulin secretion rate (ISR0-8min) in hyperglycaemic clamp (HGC)

    Measured in picomoles per minute per square meter (pmol/min/m\^2).

    Time frame: Baseline to week 28

  4. Change in second-phase insulin secretion rate (ISR20-120min) in HGC

    Measured in pmol/min/m\^2.

    Time frame: Baseline to week 28

  5. Change in total insulin secretion rate (ISR0-120min) in HGC

    Measured in pmol/min/m\^2.

    Time frame: Baseline to week 28

  6. Change in insulin secretion rate at fixed glucose concentration (ISRg) in HGC

    Measured in pmol/min/m\^2.

    Time frame: Baseline to week 28

  7. Change in total insulin response (total AUC0-120 min) in HGC

    Measured in minute \* picomoles per liter (min\*pmol/L).

    Time frame: Baseline to week 28

  8. Change in insulin response to arginine (incremental insulin AUCarginine,0-10min) in HGC

    Measured in min\*pmol/L.

    Time frame: Baseline to week 28

  9. Change in C-peptide response to arginine (incremental insulin AUCarginine,0-10min) in HGC

    Measured in min\*nmol/L.

    Time frame: Baseline to week 28

  10. Change in clamp disposition index (cDI) calculated from HEC and HGC

    cDI is defined as the product of the M-value derived from the hyperinsulinemic euglycemic clamp over the last 30 minutes and total insulin secretion (ISR AUC0-120min) derived from the insulin secretion rate based on C-peptide using the using the deconvolution technique divided by the total glucose AUC0-120min from the hyperglycemic clamp portion of the study. Measured in picomoles \* liter per square meter per square minute per kilogram (pmol\*L/m\^2/min\^2/kg).

    Time frame: Baseline to week 28

  11. Change in cDI calculated from HEC and HGC,based on lean body mass

    cDI is defined as the product of the M-value derived from the hyperinsulinemic euglycemic clamp over the last 30 minutes and total insulin secretion (ISR AUC0-120min) derived from the insulin secretion rate based on C-peptide using the using the deconvolution technique divided by the total glucose AUC0-120min from the hyperglycemic clamp portion of the study. Measured in pmol\*L/m\^2/min\^2/kg.

    Time frame: Baseline to week 28

  12. Change in β-cell glucose sensitivity (insulin secretion) from HGC

    Measured in picomoles per minute per square meter per millimoles per liter (pmol/min/m\^2/\[mmol/L\]).

    Time frame: Baseline to week 28

  13. Change in β-cell glucose sensitivity from mixed meal tolerance test (MMTT) (slope of dose-response for insulin secretion vs. plasma glucose)

    Measured in pmol/min/m\^2/(mmol/L).

    Time frame: Baseline to week 28

  14. Change in glucose concentration during MMTT (total and incremental AUC0-300min)

    Measured in minute \* millimoles per liter (min\*mmol/L).

    Time frame: Baseline to week 28

  15. Change in insulin concentration during MMTT (total and incremental AUC0-300min)

    Measured in minute \* picomoles per liter (min\*pmol/L).

    Time frame: Baseline to week 28

  16. Change in C-peptide concentration during MMTT (total and incremental AUC0-300min)

    Measured in minute \* nanomole per liter (min\*nmol/L).

    Time frame: Baseline to week 28

  17. Change in glucagon concentration during MMTT (total and incremental AUC0-300min)

    Measured in min\*pmol/L.

    Time frame: Baseline to week 28

  18. Change in fasting glucose concentration (MMTT pre-meal concentrations)

    Measured in millimole per liter (mmol/L).

    Time frame: Baseline to week 28

  19. Change in fasting insulin concentration (MMTT pre-meal concentrations)

    Measured in picomole per milliliter (pmol/mL)

    Time frame: Baseline to week 28

  20. Change in fasting C-peptide concentration (MMTT pre-meal concentrations)

    Measured in nanomoles per liter (nmol/L).

    Time frame: Baseline to week 28

  21. Change in fasting glucagon concentration (MMTT pre-meal concentrations)

    Measured in picomoles per liter (pmol/L).

    Time frame: Baseline to week 28

  22. Change in fasting proinsulin concentration (MMTT pre-meal concentrations)

    Measured in pmol/L.

    Time frame: Baseline to week 28

  23. Change in HbA1c

    Measured as percentage points (%-points).

    Time frame: Baseline to week 28

  24. Change in systolic and diastolic blood pressure

    Measured in millimeters of mercury (mmHg).

    Time frame: Baseline to week 28

  25. Number of Treatment Emergent Adverse Events (TEAEs)

    Count of events.

    Time frame: Baseline to end of study (week 34)

07

Study locations

1 site
  • Profil Institut für Stoffwechselforschung GmbH
    Neuss, 41460, Germany
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Dec 2025, 19 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 19 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2024
First posted
May 8, 2024
StartActual
May 6, 2024
Primary completionActual
Dec 28, 2025
CompletionActual
Feb 2, 2026
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06403761
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
May 8, 2024
Start date
May 6, 2024
Primary completion
Dec 28, 2025
Completion
Feb 2, 2026
Last update
Feb 27, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cagrilintide

Start the discussion